DSM Biomedical and Dechra partner to fuel innovation in animal injury recovery

Friday, December 3, 2021

DSM Biomedical announces a joint collaboration with Dechra Limited for the license and distribution of devices that create isolated solutions of highly concentrated cells and / or platelets for use with horses and companion animals.

Initially, the agreement will focus on the ProVet® APC System (Autologous Platelet Concentrate) and ProVet® BMC System (Bone Marrow Concentrate), which will complement Dechra’s existing equine and companion animal portfolio. These portable systems, weighing less than four pounds, enable regenerative medicine therapies to be easily applied wherever treatment is desired. The devices create isolated solutions of highly concentrated nucleated cells and/or platelets in less than three minutes. The combination of portability and quickness have the potential to revolutionize the use of regenerative therapies in veterinary markets.

DSM Biomedical has more than 30 years of experience in driving sustainable innovation in healthcare through their wide range of biomaterials solutions, and Dechra has a track record in developing, manufacturing, and commercializing products that positively serve the veterinary health market. Through this partnership, both companies will leverage their complementary technologies and capabilities, ultimately leading to better outcomes in support of DSM Biomedical’s vision of solving the world’s healthcare needs through sustainable science. 

Eric Shelton, VP of Global Commercial at DSM Biomedical, commented: “As a purpose-led, performance-driven business that is focused on Creating Brighter Lives for All, we could not be more excited to partner with Dechra Limited. Not only do they share the same values that we prioritize here at DSM Biomedical, but our shared synergies complement our desire to bring new biotechnology solutions into the animal healthcare market, ultimately driving innovation in regenerative medicine therapy for patients – human and animal – worldwide.”

Mike Eldred, President of Dechra North America stated: “We are extremely excited to have partnered with DSM Biomedical for their innovative and patented regenerative medicine devices. The veterinary industry has recognized that harnessing the growth factors found in platelets positively enhances healing results and reduces recovery time in soft tissue injuries.  These new products will be great additions to our companion animal and equine product lines and will further strengthen our market position in veterinary regenerative medicine.”

About Dechra
Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet APC™ (Autologous Platelet Concentrate) system and Zimeta® (dipyrone injection) further expand Dechra’s equine offerings.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com